35291-89-5

Upstream product

• 1233531-37-7 2-(4-tert-butyl-3-methoxyphenyl)isoindoline-1,3-dione 
• 79822-46-1 4-(1,1-dimethylethyl)-3-(methoxy)benzoic acid 
• 35292-23-0 1-tert-butyl-2-methoxy-4-nitrobenzene 
• 103392-84-3 2-tert-Butyl-5-nitro-phenylamine 
• 6310-21-0 2-(1,1-dimethylethyl)-benzenamine 
• 1485748-67-1 ethyl N-(4-tert-butyl-3-methoxyphenyl)carbamate 
• 442847-11-2 2-(tert-butyl)-5-nitrophenol 

Downstream Products

• 1257834-30-2 2-bromo-4-tert-butyl-5-methoxyphenylamine 
• 1257832-23-7 C₂₆H₃₃N₃O₅S 
• 1257830-46-8 N-{4-[6-tert-butyl-8-(5-fluoro-2-oxo-1,2-dihydropyridin-3-yl)-5-methoxyquinolin-3-yl]phenyl}methanesulfonamide 
• 1257830-39-9 N-[4-[6-tert-butyl-8-(2,4-dioxopyrimidin-1-yl)-5-methoxy-3-quinolyl]phenyl]methanesulfonamide 
• 1257830-24-2 N-[4-[6-tert-butyl-5-methoxy-8-(2-oxo-1H-pyridin-3-yl)-3-quinolyl]phenyl]methanesulfonamide 
• 1257830-50-4 N-[4-[6-tert-butyl-5-methoxy-8-(6-methyl-2-oxo-1H-pyridin-3-yl)-3-quinolyl]phenyl]methanesulfonamide 
• 1257830-82-2 N-[4-[6-tert-butyl-5-methoxy-8-(6-methoxy-2-oxo-1H-pyridin-3-yl)-3-quinolyl]phenyl]methanesulfonamide 
• 1257830-62-8 N-{4-[6-tert-butyl-8-(2,4-dioxo-tetrahydro-pyrimidin-1-yl)-5-methoxy-quinolin-3-yl]-phenyl}-methanesulfonamide 
• 1257830-59-3 N-[4-[6-tert-butyl-5-methoxy-8-(2-oxohexahydropyrimidin-1-yl)-3-quinolyl]phenyl]methanesulfonamide 
• 1485748-91-1 N-[4-[6-tert-butyl-8-(5-fluoro-2-methoxy-3-pyridyl)-5-methoxy-3-quinolyl]phenyl]methanesulfonamide 
• 1257832-25-9 N-[4-(8-amino-6-tert-butyl-5-methoxy-3-quinolyl)phenyl]methanesulfonamide 
• 1257830-36-6 N-[4-(8-bromo-6-tert-butyl-5-methoxy-3-quinolyl)phenyl]methanesulfonamide 
• 1485749-47-0 N-[4-[6-tert-butyl-8-(2,4-dimethoxypyrimidin-5-yl)-5-methoxy-3-quinolyl]phenyl]methanesulfonamide 
• 1485749-49-2 N-[4-[6-tert-butyl-5-methoxy-8-(4-methoxy-1-methyl-2-oxo-pyrimidin-5-yl)-3-quinolyl]phenyl]methanesulfonamide 

Relevant academic research and scientific papers

Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

Discovery of N-[4-[6-tert-butyl-5-methoxy-8-(6-methoxy-2-oxo-1 H -pyridin-3-yl)-3-quinolyl]phenyl]methanesulfonamide (RG7109), a potent inhibitor of the hepatitis C virus NS5B polymerase

In the past few years, there have been many advances in the efforts to cure patients with hepatitis C virus (HCV). The ultimate goal of these efforts is to develop a combination therapy consisting of only direct-antiviral agents (DAAs). In this paper, we

MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS

The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.

COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR

The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating diseases using such CFTR modulators.

HETEROCYCLIC ANTIVIRAL COMPOUNDS

Compounds having the formula I wherein wherein R1, R2, R3, R4, X1, X2, X3 and X4 and as defined herein are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication.